Report of a heavily pretreated ovarian clear cell carcinoma patient who showed a meaningful response to HER2-directed antibody drug conjugate despite low HER2 expression.
Key Takeaways
- Formatted version of the article will be published soon
- You have multiple emails registered with Frontiers: You don't have a Frontiers account ?
- You can register here Ovarian clear cell carcinoma (OCCC)